The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'

Michele Basso, Vincenzo Dadduzio, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Mariantonietta Di Salvatore, Armando Orlandi, Valeria Zurlo, Vincenzo Di Noia, Carlo Barone

Research output: Contribution to journalArticle

Abstract

This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.

Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalPersonalized Medicine
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

oxaliplatin
Survival
Colorectal Neoplasms
Randomized Controlled Trials
Physicians
Drug Therapy
Therapeutics
Neoplasms

Cite this

The interference between oxaliplatin & anti-EGFR therapies : a different hypothesis to explain the 'unexplainable'. / Basso, Michele; Dadduzio, Vincenzo; Rossi, Sabrina; D'Argento, Ettore; Strippoli, Antonia; Di Salvatore, Mariantonietta; Orlandi, Armando; Zurlo, Valeria; Di Noia, Vincenzo; Barone, Carlo.

In: Personalized Medicine, Vol. 15, No. 4, 01.07.2018, p. 319-327.

Research output: Contribution to journalArticle

Basso, M, Dadduzio, V, Rossi, S, D'Argento, E, Strippoli, A, Di Salvatore, M, Orlandi, A, Zurlo, V, Di Noia, V & Barone, C 2018, 'The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'', Personalized Medicine, vol. 15, no. 4, pp. 319-327. https://doi.org/10.2217/pme-2017-0082
Basso, Michele ; Dadduzio, Vincenzo ; Rossi, Sabrina ; D'Argento, Ettore ; Strippoli, Antonia ; Di Salvatore, Mariantonietta ; Orlandi, Armando ; Zurlo, Valeria ; Di Noia, Vincenzo ; Barone, Carlo. / The interference between oxaliplatin & anti-EGFR therapies : a different hypothesis to explain the 'unexplainable'. In: Personalized Medicine. 2018 ; Vol. 15, No. 4. pp. 319-327.
@article{b461e0cd00ce4390ae164ca517e0efc8,
title = "The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'",
abstract = "This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.",
author = "Michele Basso and Vincenzo Dadduzio and Sabrina Rossi and Ettore D'Argento and Antonia Strippoli and {Di Salvatore}, Mariantonietta and Armando Orlandi and Valeria Zurlo and {Di Noia}, Vincenzo and Carlo Barone",
year = "2018",
month = "7",
day = "1",
doi = "10.2217/pme-2017-0082",
language = "English",
volume = "15",
pages = "319--327",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - The interference between oxaliplatin & anti-EGFR therapies

T2 - a different hypothesis to explain the 'unexplainable'

AU - Basso, Michele

AU - Dadduzio, Vincenzo

AU - Rossi, Sabrina

AU - D'Argento, Ettore

AU - Strippoli, Antonia

AU - Di Salvatore, Mariantonietta

AU - Orlandi, Armando

AU - Zurlo, Valeria

AU - Di Noia, Vincenzo

AU - Barone, Carlo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.

AB - This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.

U2 - 10.2217/pme-2017-0082

DO - 10.2217/pme-2017-0082

M3 - Article

C2 - 29927360

VL - 15

SP - 319

EP - 327

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 4

ER -